REPROCELL News

Corporate News tagged:

Clinical capabilities (2)

REPROCELL Corporate News

VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL

18 May 2021

19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.

19 April 2021

Launch of New Testing Service of Identification for Covid-19 Variants

08 April 2021

REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan

22 March 2021

REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products

17 March 2021

Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India

11 March 2021

REPROCELL launches PCR Testing Service for COVID-19

01 March 2021

REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®

25 February 2021

REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers

17 December 2020

REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research

17 August 2020

REPROCELL’s Personal iPS Service is Launched in Japan

15 July 2020

Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient

28 February 2020

Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan

01 August 2018

Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

22 November 2016

Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy

11 November 2016

Previous 1 2

Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

About REPROCELL

Make an inquiry